Tadalafil Tablet, Film Coated
Product Images NDC 50090-7314

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 50090-7314). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500907314)

Tadalafil 5 mg oral film-coated tablets label from A-S Medication Solutions. The label displays product NDC 50090-7314-0 and contains 90 tablets. Storage instructions specify to keep at 77 degrees Fahrenheit. The label includes dosage instructions as directed by a package insert and notes Libertyville, Illinois as the manufacturer location.*

FDA Label Image

Chemical Structure (Tadalafil 1)

Chemical structure diagram of Tadalafil, showing its molecular framework composed of multiple rings and functional groups consistent with the active ingredient tadalafil.*

FDA Label Image

Tadalafil-tablets-figure-1 (Tadalafil 2)

A set of four line graphs showing the blood pressure effects of tadalafil compared to placebo over time. The graphs depict standing systolic and diastolic blood pressure and supine systolic and diastolic blood pressure, with the y-axes indicating the difference in mmHg and the x-axes representing time in hours up to 96 hours post-administration.*

FDA Label Image

Tadalafil-tablets-figure-2 (Tadalafil 3)

Two line graphs showing the effects on systolic blood pressure over time. The top graph displays standing systolic blood pressure (mmHg) versus time post-dose (hours), comparing tadalafil 20 mg with doxazosin 8 mg against placebo with doxazosin 8 mg. The bottom graph shows supine systolic blood pressure (mmHg) over the same time period for the same treatments.*

FDA Label Image

Tadalafil-tablets-figure-3 (Tadalafil 4)

A line graph showing systolic blood pressure (mmHg) changes over 12 hours after administration of tadalafil or placebo combined with 8 mg doxazosin, with four data series representing different dosing times and treatments.*

FDA Label Image

Tadalafil-tablets-figure-4 (Tadalafil 5)

A line graph showing plasma tadalafil concentration (μg/L) over time (hours) for three dosing regimens: a single 20-mg dose, a single 5-mg dose, and once-daily 5-mg dosing following 5 consecutive days of administration. The y-axis represents plasma concentration, and the x-axis represents time in hours, with error bars indicating variability.*

FDA Label Image

Table 5 (Tadalafil 6)

A line graph comparing the change from baseline in IPSS Total Score over 12 weeks of treatment. The x-axis represents treatment duration in weeks (0, 4, 8, 12), and the y-axis shows the change from baseline scores. Two lines compare tadalafil 5 mg and placebo, with tadalafil showing a greater decrease in score over time.*

FDA Label Image

Table 6 (Tadalafil 7)

A line graph comparing change from baseline in IPSS total score over 12 weeks of treatment with tadalafil 5 mg versus placebo. The x-axis shows duration of treatment in weeks (0, 1, 4, 8, 12), and the y-axis shows changes from baseline in the IPSS total score. Two lines illustrate the decreasing symptom scores over time, with tadalafil showing a greater reduction compared to placebo, with significant difference noted (p<0.01).*

FDA Label Image

Tadalafil-tablets-figure-7 (Tadalafil 8)

A line graph depicting the least squares mean change from baseline over 26 weeks of therapy. The graph compares two groups: Tadalafil/Finasteride and Placebo/Finasteride, with data points at weeks 0, 4, 12, and 26. The Tadalafil/Finasteride group shows a greater reduction from baseline compared to Placebo/Finasteride at each time point noted.*

FDA Label Image

Image 8 (Tadalafil 9)

A line graph comparing change from baseline in IPSS total score over 12 weeks of treatment between tadalafil 5 mg and placebo groups. The x-axis represents treatment duration in weeks, and the y-axis represents change in IPSS score. The tadalafil group shows a greater reduction in score compared to placebo at all measured times.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.